REGNRegeneron PharmaceuticalsRunning, no new patients
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
B-Cell Non-Hodgkin Lymphoma (B-NHL)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 216 (final count)
- Started
- Feb 15, 2024
- Main results expected
- May 29, 2028
- Fully finished
- May 29, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-free survival (EFS) as assessed by independent central review (ICR)
Measured over: Assessed up to 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06230224 · record last updated 2026-05-11 · checked 2026-11-09 15:47 UTC